Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for International Journal of Endocrinology, enter your email address in the box below.

International Journal of Endocrinology
Volume 2016, Article ID 8580750, 7 pages
http://dx.doi.org/10.1155/2016/8580750
Research Article

Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup

Ze Rui Wu,1 Yong Zhang,1 Lin Cai,1 Shao Jian Lin,2 Zhi Peng Su,1 Yong Xu Wei,2 Han Bing Shang,2 Wen Lei Yang,2 Wei Guo Zhao,2 and Zhe Bao Wu1,2

1Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
2Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received 10 July 2016; Accepted 24 October 2016

Academic Editor: Aldo E. Calogero

Copyright © 2016 Ze Rui Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao, “Advances in the treatment of prolactinomas,” Endocrine Reviews, vol. 27, no. 5, pp. 485–534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. B. W. Zhe, J. Y. Chun, P. S. Zhi, C. Z. Qi, S. W. Jin, and M. Z. Wei, “Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up,” Journal of Neurosurgery, vol. 104, no. 1, pp. 54–61, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. F. F. Casanueva, M. E. Molitch, J. A. Schlechte et al., “Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas,” Clinical Endocrinology, vol. 65, no. 2, pp. 265–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Melmed, F. F. Casanueva, A. R. Hoffman et al., “Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Colao and S. Savastano, “Medical treatment of prolactinomas,” Nature Reviews Endocrinology, vol. 7, no. 5, pp. 267–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Bevan, J. Webster, C. W. Burke, and M. F. Scanlon, “Dopamine agonists and pituitary tumor shrinkage,” Endocrine Reviews, vol. 13, no. 2, pp. 220–240, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Caccavelli, F. Feron, I. Morange et al., “Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas,” Neuroendocrinology, vol. 60, no. 3, pp. 314–322, 1994. View at Google Scholar · View at Scopus
  8. Z. B. Wu, W. M. Zheng, Z. P. Su et al., “Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior,” Journal of Neuro-Oncology, vol. 99, no. 1, pp. 25–32, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Knosp, E. Steiner, K. Kitz et al., “Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings,” Neurosurgery, vol. 33, no. 4, pp. 610–618, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. R. K. Shrivastava, M. S. Arginteanu, W. A. King, and K. D. Post, “Giant prolactinomas: clinical management and long-term follow up,” Journal of Neurosurgery, vol. 97, no. 2, pp. 299–306, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Corsello, G. Ubertini, M. Altomare et al., “Giant prolactinomas in men: efficacy of cabergoline treatment,” Clinical Endocrinology, vol. 58, no. 5, pp. 662–670, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. A. B. Moraes, C. Marques Dos Santos Silva, L. Vieira Neto, and M. R. Gadelha, “Giant prolactinomas: the therapeutic approach,” Clinical Endocrinology, vol. 79, no. 4, pp. 447–456, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. Z. B. Wu, Z. P. Su, J. S. Wu, W. M. Zheng, Q. C. Zhuge, and M. Zhong, “Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion,” Pituitary, vol. 11, no. 1, pp. 63–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Maiter and E. Delgrange, “Therapy of endocrine disease: the challenges in managing giant prolactinomas,” European Journal of Endocrinology, vol. 170, no. 6, pp. R213–R227, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. X. H. Lou, Z. B. Wu, and Y. Z. Zhang, “Bromocriptine-induced brainstem angulation in a patient with invasive prolactinoma,” Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 3, pp. 867–868, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Di Sarno, M. L. Landi, P. Cappabianca et al., “Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5256–5261, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Colao, A. Di Sarno, F. Sarnacchiaro et al., “Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 3, pp. 876–883, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. M. H. Almalki, B. Buhary, S. Alzahrani et al., “Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases,” Pituitary, vol. 18, no. 3, pp. 405–409, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. S. V. Acharya, R. A. Gopal, P. S. Menon, T. R. Bandgar, and N. S. Shah, “Giant prolactinoma and effectiveness of medical management,” Endocrine Practice, vol. 16, no. 1, pp. 42–46, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Shimon, C. Benbassat, and M. Hadani, “Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men,” European Journal of Endocrinology, vol. 156, no. 2, pp. 225–231, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. R. E. Davis, M. C. Sheppard, and D. A. Heath, “Giant invasive prolactinoma: a case report and review of nine further cases,” Quarterly Journal of Medicine, vol. 74, no. 275, pp. 227–238, 1990. View at Google Scholar · View at Scopus
  22. A. Chattopadhyay, A. Bhansali, and S. R. Masoodi, “Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men,” Pituitary, vol. 8, no. 2, pp. 147–154, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. C. M. Barrera, A. E. Ruiz, and W. A. Banks, “A giant prolactinoma and the effect of chronic bromocriptine therapy on basal and TRH-stimulated serum prolactin levels,” Hormone Research, vol. 35, no. 3-4, pp. 167–169, 1991. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Berwaerts, J. Verhelst, R. Abs, B. Appel, and C. Mahler, “A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature,” Journal of Endocrinological Investigation, vol. 23, no. 6, pp. 393–398, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Espinosa, E. Sosa, V. Mendoza, C. Ramírez, V. Melgar, and M. Mercado, “Giant prolactinomas: are they really different from ordinary macroprolactinomas?” Endocrine, vol. 52, no. 3, pp. 652–659, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. F. Fraioli, F. Novegno, E. Catena, C. Fraioli, and L. Moschettoni, “Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children,” Child's Nervous System, vol. 26, no. 9, pp. 1233–1237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. V. Fernandes, M. J. Santos, R. Almeida, and O. Marques, “Ten-year follow-up of a giant prolactinoma,” BMJ Case Reports, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. D. K. Hamilton, M. L. Vance, P. T. Boulos, and E. R. Laws, “Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists,” Pituitary, vol. 8, no. 1, pp. 53–60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Primeau, C. Raftopoulos, and D. Maiter, “Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients,” European Journal of Endocrinology, vol. 166, no. 5, pp. 779–786, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Kim, C. Clelland, I. Yang, and N. Pouratian, “Comprehensive review of stereotactic radiosurgery for medically and surgically refractory pituitary adenomas,” Surgical Neurology International, vol. 3, supplement 2, pp. S79–S89, 2012. View at Publisher · View at Google Scholar
  31. E. Delgrange, T. Daems, J. Verhelst, R. Abs, and D. Maiter, “Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients,” European Journal of Endocrinology, vol. 160, no. 5, pp. 747–752, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Delgrange, J. Trouillas, D. Maiter, J. Donckier, and J. Tourniaire, “Sex-related difference in the growth of prolactinomas: A Clinical and Proliferation Marker Study,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 7, pp. 2102–2107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Delgrange, T. Duprez, and D. Maiter, “Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy,” Clinical Endocrinology, vol. 64, no. 4, pp. 456–462, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Salenave, D. Ancelle, T. Bahougne et al., “Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 100, no. 3, pp. 1177–1186, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. J. Verhelst, R. Abs, D. Maiter et al., “Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 7, pp. 2518–2522, 1999. View at Publisher · View at Google Scholar · View at Scopus